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A B S T R A C T   
Factor X deficiency is a rare coagulation disorder that can be hereditary or acquired. The typology and severity of 
the associated bleeding symptoms are highly heterogeneous, adding to the difficulties of diagnosis and man-
agement. Evidence-based guidelines and reviews on factor X deficiency are generally limited to publications 
covering a range of rare bleeding disorders. Here we provide a comprehensive review of the literature on factor X 
deficiency, focusing on the hereditary form, and discuss the evolution in disease management and the evidence 
associated with available treatment options. Current recommendations advise clinicians to use single-factor 
replacement therapy for hereditary disease rather than multifactor therapies such as fresh frozen plasma, cry-
oprecipitate, and prothrombin complex concentrates. Consensus in treatment guidelines is still urgently needed 
to ensure optimal management of patients with factor X deficiency across the spectrum of disease severity.   
1. Introduction 
Factor X deficiency is a rare coagulation disorder that is either he-
reditary (i.e. an autosomal recessive condition) or acquired (usually due 
to amyloidosis) [1,2]. Given the rarity of the disorder, currently avail-
able reviews and guidance on the management of factor X deficiency 
generally form a relatively small component within larger publications 
addressing the diagnosis and management of multiple rare coagulation 
disorders [3–7]; indeed, a review of the literature uncovered only one 
authoritative factor X–focused review, published in 2008 [8], and only 
one publication in the past 5 years specifically concerned with the 
treatment of factor X deficiency [9]. 
We therefore sought to review the published literature on factor X 
deficiency and summarize current knowledge on the diagnosis and 
management of factor X deficiency, focusing in particular on hereditary 
disease. In addition, in view of the recent introduction of new treatments 
for factor X deficiency, we describe the evolution of treatments to 
manage factor X deficiency and discuss the advantages and disadvan-
tages of each treatment type along with the treatment options in specific 
circumstances requiring special consideration. It is hoped that this 
exposition will help to bridge current gaps in our knowledge and high-
light areas where further research is required, such as the minimum 
concentration of factor X required for hemostasis, as well as address the 
need for recommendations concerning the optimal management of 
factor X–deficient patients. 
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2. Methods 
A literature search was conducted in the US National Library of 
Medicine PubMed database for publications indexed for the major 
Medical Subject Headings (MeSH) term “Factor X Deficiency” and 
published in the English language since 1990. Additional relevant 
publications were identified from citations within relevant reviews and 
guidelines, such as the United Kingdom Haemophilia Centre Doctors’ 
Organization (UKHCDO) guidelines on rare coagulation disorders [4]. 
This was supplemented by published abstracts presented at recent 
relevant conferences (annual meetings of the American Society of He-
matology from 2015 to 2017 and the International Society on Throm-
bosis and Hemostasis from 2015 to 2018) that contain the phrase “factor 
X deficiency” or “FX deficiency.” 
Publications were manually selected from the search results that 
addressed key topics of interest: disease presentation/etiology/diag-
nosis; treatment (plasma, prothrombin, factor IX and X replacement, and 
prophylactic treatment); management under special situations, notably 
pregnancy, surgery, intracranial bleeding, and severe disease (bleeding 
within the central nervous system [CNS] or gastrointestinal [GI] tract); 
and other considerations (in particular, phenotype/genotype correlation 
and acquired factor X deficiency). In areas in which few publications 
were identified, additional searches without MeSH or date limitations 
were conducted as necessary to ensure that all topics of interest were 
adequately addressed. 
3. Hereditary factor X deficiency: overview and diagnosis 
3.1. Disease overview 
Hereditary factor X deficiency is an autosomal recessive disorder of 
the F10 gene that causes a variable reduction in plasma factor X coag-
ulant activity (FX:C), in which decreasing FX:C activity is correlated 
with increasing bleeding severity [3,4,8,10,11]. In a cross-sectional 
study using data from the European Network of Rare Bleeding Disor-
ders (EN-RBD), FX:C levels at which patients were asymptomatic or had 
grade 1, 2, or 3 bleeding were 56, 40, 25, and <10 IU/dL, respectively 
[10]. A similar classification has been proposed based on data from the 
EN-RBD registry, in which patients with factor X activity levels of >40, 
10–40 and <10 IU/dL are classified as being largely asymptomatic, 
suffering minor spontaneous or triggered bleeding, or having a high risk 
of major spontaneous bleeding, respectively [12]. The disorder is 
sometimes further classified into type I disease (low coagulant activity 
and low immunological antigen levels) or type II disease (low coagulant 
activity and normal/borderline low antigen levels) [1,11,13]. 
The most severe form of the disease is rare, resulting from homozy-
gous or compound heterozygous hereditary defects. The overall distri-
bution of patients with factor X deficiency corresponds to approximately 
8% of the total number of patients with rare blood disorders, yielding a 
worldwide prevalence of 1:1,000,000 [5,6,14]. However, in countries 
and regions in which consanguineous marriage is common, such as Iran, 
southern India, Pakistan, and Latin America, severe factor X deficiency 
occurs 8 to 10 times more frequently than in other regions [1,6,15–17]. 
While the heterozygous form of the disease is much more common 
(prevalence approximately 1:500 worldwide), it is associated with only 
a mild reduction in plasma FX:C (functional activity >30%) and is 
usually clinically asymptomatic [3]. 
Clinical manifestations are most commonly seen as mucocutaneous 
bleeds (particularly epistaxis), hemarthroses (soft tissue and joint 
bleeding), GI bleeding, and heavy menstrual bleeding [1,3–5,16,18–20]. 
In a review of 32 cases in Iran, these symptoms were reported in 72%, 
69%, 38%, and 50% of patients, respectively, and in 61%, 77%, 66%, 
and 60% of those with severe factor X deficiency (FX:C levels of <10 IU/ 
dL, n = 18), respectively [19]. Other symptoms seen in more severe 
cases include severe postoperative hemorrhage and CNS bleeding. 
Although CNS/intracranial hemorrhage occurs less frequently (being 
reported in 9%–21% of symptomatic cases of factor X deficiency 
[4,16,17,19]), it is a major concern, as it can be a presenting symptom of 
severe factor X deficiency at birth; patients may present at any age, but 
the most severe forms of disease become apparent at an early age, 
typically with umbilical stump or CNS bleeding in the newborn [1,5]. 
Patients with moderately severe disease (FX:C 1–5 IU/dL) are likely 
to bleed as a result of hemostatic challenge (e.g. trauma and surgery), 
while those with mild factor X deficiency may remain undiagnosed until 
they participate in routine screening or family studies [3]. Mild bleeding 
may occur in some heterozygous patients, typically after surgery, tooth 
extraction, trauma, or childbirth [17,21]. 
3.2. Genetic variants 
As may be expected given the wide range in impact of the disease on 
FX:C levels, the genetic profile of factor X deficiency is varied [22–24]. 
The most common sites of mutation have been localized to the glutamic 
acid domain on exon 2 [8,22,24] and the catalytic site of factor X on 
exons 7 and 8, which are critically important in the functional activity of 
this protein [8,11]. Most mutations are reported to be missense muta-
tions unique to a particular patient or family [1,8,11,13,22,25]. How-
ever, there is no clear link between the genotype/location of the 
mutation and the phenotypic expression of the disease [1,26,27]. 
Consistent with animal findings, complete absence of factor X is 
incompatible with life [11]. 
3.3. Assays for diagnosis 
Prolongation of the prothrombin time (PT) and/or activated partial 
thromboplastin time (APTT) that can be corrected in a 50:50 mix with 
normal plasma are suggestive of either deficiency or an inhibitor of the 
final common pathway, and specific coagulation factor assays are 
necessary to determine which factors are deficient. The diagnosis of 
factor X deficiency may be confirmed by quantifying plasma FX:C 
through serial dilutions with factor X–deficient plasma [1,3,4,8]. 
Although such one-stage PT- or APTT-based clotting assays are sufficient 
to diagnose factor X deficiency, the corresponding degrees of prolon-
gation may be influenced by differences in sensitivity between types of 
thromboplastin. 
Additional methods available to support diagnosis include the dilute 
Russell Viper Venom (RVV) assay (a metalloproteinase that activates 
factor X directly and can therefore detect factor X deficiency in plasma 
samples), chromogenic assays (spectrophotometric detection of a sub-
strate sensitive to activated factor X), and immunological assays (e.g. an 
enzyme-linked immunosorbent assay [ELISA] that measures factor X 
antigen) [3,4,8], though these assays cannot be used as screening tests 
for factor X deficiency given the false-normal values in patients with 
type II disease [1,3,8]. Cases of patients with factor X deficiency 
showing normal RVV assay results have also been reported [26,28,29]. 
This unexpected result was associated with a variety of genetic muta-
tions and factor X dysfunction. While these methods may provide 
interesting or supportive information, measurement of factor X activity 
alone suffices to assess disease severity. 
Concerns over the variability and reliability of test results, which 
depend on factors such as the type of anticoagulant used, sample ship-
ping and centrifugation prior to analysis, the storing of reagents, 
equipment maintenance, and the use of internal/external quality con-
trol, have led to the development of laboratory standards [1]. Despite 
this, studies using both chromogenic and clotting assays have demon-
strated differences between the two methods, depending on both the 
standard preparation used in the assay and the analytical method; 
however, the authors reporting these results have deemed this unlikely 
to be of clinical significance and noted that adjustments can be incor-
porated to accommodate any minor differences [30,31]. 
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4. Evolution of treatment 
Historically, bleeding episodes in patients with coagulation disorders 
were treated with whole blood replacement and later with fresh frozen 
plasma (FFP) products. More recently, with further elucidation of the 
role of specific coagulation factors and advances in technological abili-
ties, a range of coagulation factor concentrates have been developed as 
replacement therapies [7]. For hereditary factor X deficiency, current 
therapeutic options include FFP, cryoprecipitate, prothrombin complex 
concentrates (PCCs), dual-factor therapy (factor IX/X), and human 
plasma–derived factor X concentrate (pdFX). 
4.1. Plasma 
Historically, hereditary factor X deficiency has been treated by 
plasma replacement therapy. Although virally inactivated FFP is now 
preferred to the native form, it is not universally available [1,7,9,32]. 
Typically, virally inactivated FFP is administered once daily (20 mL/ 
kg then 3–6 mL/kg), aiming to maintain FX:C trough levels above 10–20 
IU/dL [3]. Such levels are usually sufficient to treat hemarthrosis and 
soft tissue bleeding, but higher levels may be required for severe 
bleeding or surgery [33]. 
Concerns with this treatment include allergic reactions, the need for 
adequate pathogen inactivation, the increased risk of transfusion-related 
acute lung injury due to the unknown concentrations of other coagula-
tion factors, delayed efficacy, physiologic differences in the hemostatic 
system of neonates and young children versus older patients, fluid 
overload due to the large volume required to achieve sufficiently high 
plasma FX:C levels, and the variable levels of vitamin K-dependent 
clotting factors in FFP, including FX [1,8,9,34–37]. Approaches to 
overcome some of these issues include antihistamine premedication in 
patients with a history of allergy; solvent-detergent processing for 
pathogen removal, though this may cause some loss of coagulation 
factors); the elimination of leukocyte antibodies that precipitate 
transfusion-related injuries by using plasma only from men, women who 
have not been pregnant, or women who have tested negative for human 
leukocyte antigen antibodies; and using slower infusion rates or di-
uretics to reduce the risk of fluid overload [38,39]. 
An additional concern is the substantial variability between plasma 
products, which may impact treatment efficacy [40]; substantial dif-
ferences have been observed in the half-life of factor X when infused as 
FFP or plasma complex concentrates, with values ranging from 17 to 40 
hours [41–43]. In addition, studies using FFP as the factor X source in 
two patients with undetectable levels of factor X showed considerable 
intra- as well as interindividual variation in apparent factor X half-life. 
However, there have been no reported cases of anti–factor X inhibi-
tory antibodies developing in patients treated with FFP [8,41]. 
4.2. Cryoprecipitate 
Early attempts to create improved factor VIII concentrates from 
pooled plasma in the early 1960s led to the discovery of cryoprecipitate, 
which is enriched in fibrinogen, factor VIII, von Willebrand factor, and 
factor XIII [44]. Cryoprecipitate is commonly prepared from thawed FFP 
(made from plasma processed within 8 hours of collection) or from 
whole blood processed within 24 hours of collection, which is then 
centrifuged to remove the supernatant and yield the insoluble precipi-
tate [44,45]. Without viral inactivation, cryoprecipitate was viewed as 
an unacceptably high-risk product, able to transmit viral infection [46]. 
This led to its withdrawal from many European countries, although 
cryoprecipitate remains available for hemostatic therapy in several 
countries, including the United States and Canada [44]. The effective-
ness of cryoprecipitate in achieving therapeutic levels of factor X may be 
limited [4,7], and the cost of virus-inactivated cryoprecipitate may 
actually be greater than that of specific factors in some countries. 
Therefore, if single-factor concentrate is available, it should be used 
rather than cryoprecipitate. However, where a single-factor concentrate 
is unavailable, cryoprecipitate that has been virus inactivated (e.g. by 
methylene blue treatment or solvent-detergent treatment) has potential 
value. 
4.3. Prothrombin complex concentrates 
The therapeutic options available for treating factor X deficiency 
increased with the approval of plasma-derived, virally inactivated PCCs, 
at which point PCC treatment quickly came to be preferred over the use 
of FFP, at least in the United States and Canada [3,8,9,20,47]. Several 
PCC products are now available, as summarized in Table 1. However, in 
the European Union, the use of PCCs for factor X deficiency has been 
limited to the treatment of bleeding and perioperative prophylaxis in 
congenital deficiency of vitamin K–dependent factors II and X when a 
purified specific coagulation factor product is not available. PCCs typi-
cally include three or four coagulation factors (factors II, IX, and X, with 
or without factor VII), and most also include one or more other factors 
with anticoagulant activity, such as heparin, antithrombin, protein C, 
protein S, and/or protein Z [9,47,48]. The various products differ in the 
relative content of each coagulation factor, and there may also be 
variability between product batches [1,9]. This variability poses a 
particular risk for patients with severe symptoms, who require frequent 
infusions [1,47–50]. 
As PCCs were originally developed for the treatment of factor IX 
deficiency (hemophilia B), the focus in product labelling and dosing 
guidelines is on the concentration of factor IX. Most PCC products have 
approximately equivalent factor IX and X activity and increase plasma 
levels by approximately 1.5%/IU/kg body weight; a typical 20–30 IU/kg 
dose of factor IX is expected to increase plasma FX:C activity by 40–60 
IU/dL [4,8]. PCCs do not generally require daily administration due to 
the long half-life of factor X (approximately 30 hours) [4,8], though 
there is substantial variability in the half-life of factor X infused as PCCs. 
The efficacy of PCC administration has been reported in several small 
case series for various uses in patients with FX deficiency, including 
prophylaxis in patients with severe factor X deficiency, control of minor 
bleeding episodes, and hemostatic cover during surgical procedures, but 
in patients with recurrent intracranial hemorrhage, outcomes have 
varied depending on the plasma factor X levels achieved [1,3,8,20]. This 
has led to PCC dosing guidance indicating that 20–30 IU/kg (factor IX) 
should increase plasma factor X activity by 40–60 IU/dL, with further 
infusions required daily or every 2 days if sustained treatment is 
required [1,4]. However, there remains a lack of consensus among 
evidence-based recommendations regarding PCC use in different coun-
tries, as well as insufficient evidence to establish differences in efficacy 
and safety between three- and four-factor PCCs [47]. 
Concerns associated with PCC administration for factor X deficiency 
include the unknown concentrations of factors II, VII, and X and the 
increased risk of thrombosis [1,9,51]. The risk of thrombosis with PCCs 
appears be related to differences in product quality, the dose adminis-
tered, infusion rates, and/or patient characteristics/risk profile, with 
thrombotic events associated with PCC administration observed more 
frequently among patients with acquired hemostatic disorders than in 
those with hereditary coagulation deficiencies [9,48,51]. Increased 
levels of factors VII, IX, and/or X do not appear to influence total 
thrombin generation; rather, evidence suggests that the most likely 
determinant of this thrombotic risk is the accumulation of prothrombin 
(factor II) due to its long half-life, along with the balance between this 
coagulation factor and coagulation inhibitors [48]. Since the half-lives 
of the different coagulation factors differ widely (from 6 hours for fac-
tor VII to 20 hours for factor IX, 30  hours for factor X, and 60 hours for 
factor II), repeated dosing can lead to accumulation of factors II and X. 
Consequently, care should be exercised during repeated or long-term 
PCC administration, and the inclusion of coagulation inhibitors such 
as protein C, protein S, and protein Z or antithrombin should be 
considered, particularly for patients with liver disease [48]. The 
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UKHCDO guidelines note that PCCs should be used with caution, if at all, 
in patients with liver disease, large hematomas, major trauma, or anti-
thrombin deficiency as well as in neonates [3]. 
As with FFP, PCC administration has not been associated with the 
development of inhibitory antibodies in patients with factor X deficiency 
[8], though antibody formation has been reported with other uses of 
PCCs [49]. 
4.4. Factor IX and X replacement 
Freeze-dried concentrate containing specified amounts of human 
factors IX and X was developed in response to concerns about variability 
in coagulation factors in PCCs [1] and potential fluid overload or 
inability to maintain therapeutic levels with repeated administration 
[7]. Among the many factor IX products available, most contain multiple 
additional coagulation factors. However, available products also include 
a dual factor IX and factor X (Factor X P Behring [CSL Behring AG, Bern, 
Switzerland]) and several single-factor products. The two-factor product 
is a powder formulation containing 600–1200 IU human coagulation 
factor X and 600 IU human coagulation factor IX per vial, along with 
antithrombin III and heparin [52], and it is currently licensed only in 
Switzerland. Single-factor products include Immunine VH (Baxter AG, 
Vienna, Austria), a highly purified freeze-dried concentrate of virally 
inactivated pooled human blood coagulation factor IX also containing 
trace amounts of other coagulation factors (<0.02 IU of factors II, VII, 
and X per IU of factor IX) and heparin (<0.1 IU/mL) [53]. Another 
option is AlphaNine® SD (Grifols Biologicals, Inc., Los Angeles, CA, 
USA), a purified, virus-filtered lyophilized powder formulation of factor 
IX derived from human plasma that also contains trace amounts of factor 
VII (<0.04 U/IU factor IX), factor II (<0.05 U/IU), factor X (<0.05 U/ 
IU), and heparin (<0.04 U/IU) [54]. 
The efficacy of dual-factor therapy in subjects with factor X defi-
ciency has been reported in two studies. The most recent study followed 
10 subjects with severe factor X deficiency who were given prophylactic 
therapy with Behring Factor X P (20 IU/kg administered weekly) for 1 
year. The nine subjects who tolerated the treatment and remained on 
therapy for the full year all achieved factor X levels of ≥1 IU/dL and had 
no bleeding symptoms; one patient stopped treatment after the first 
infusion due to an anaphylactic reaction [55]. An earlier analysis of data 
from the Greifswald Registry showed that bleeding episodes in seven 
patients with factor X deficiency were well controlled using regular 
prophylaxis with another dual-factor product, Factor IX HS® (ZLB 
Behring [now CSL Behring]), a plasma-derived, pasteurized concentrate 
containing approximately 800 IU factor X and 1200 IU factor IX [56]. 
Of these factor IX/X products, only Behring Factor X P is approved 
for the treatment of factor X deficiency, and, as previously noted, this 
product is available only in Switzerland; at the time of licensing, no 
clinical trials had been performed with the product in subjects with 
factor X deficiency due to the rarity of the disease. Consequently, dosage 
recommendations are based on published information mainly derived 
from treatment of factor X–deficient patients with plasma or PCCs [52] 
plus the single study of Factor X P that has since been published [55]. 
Adverse events potentially associated with factor IX/X treatment 
include hypersensitivity reactions, thrombosis (which necessitates 
monitoring of factor IX levels and D-dimer), nephrotic syndrome, and 
the development of neutralizing antibodies [1,9,52,57]. 
4.5. Factor X replacement 
Recognition of the advantages of single-factor concentrates over 
plasma or PCC replacement therapy for rare bleeding disorders [7,9,58] 
led to the development of Coagadex® (Bio Products Laboratory Ltd), a 
high-purity, high-potency pdFX formulation that represents the first and 
only available treatment specifically for hereditary factor X deficiency 
[59–61]. In Europe, pdFX is indicated in all age groups for the treatment 
and prophylaxis of bleeding episodes and for perioperative management 
of bleeding in patients with hereditary factor X deficiency [60]. In the 
United States, it has been approved for use in adults and children with 
hereditary factor X deficiency for routine prophylaxis to reduce the 
frequency of bleeding episodes, for on-demand treatment and control of 
bleeding episodes, and for perioperative management of bleeding in 
patients with mild and moderate hereditary factor X deficiency [59]. 
Table 1 
Overview of PCC products previously or currently available in Europe, the United States, or Canada [1,4,47–50,96–109].a  
Product name, content Manufacturer or marketing authorization 
holder 
Purification Factor X content (IU 
relative to factor IX) 
Coagulation proteins and other 
antithrombic additions 
FEIBA NF or VH, PCC [108] Baxalta US Inc./Shire/Baxter Healthcare 
Corporation 
Vapor heat, nanofiltration, 
DEAE-Sephadex adsorption 
NA None 
Proplex-T, 4-factor PCC [109] Baxter Healthcare Corporation Dry heat 100 Antithrombin, heparin 
Prothromplex Total, 4-factor 
PCC [96] 
Baxter Bioscience, Baxalta Innovations 
GmbH, Shire Pharmaceuticals Ltd 
Vapor heat 100 Antithrombin, heparin 
Prothromplex TIM3, 3-factor 
PCC 
Baxter SpA  100  
Beriplex® P/N, 4-factor PCC 
[99–101] 
CSL Behring Pasteurization, nanofiltration 110–190 Antithrombin, heparin, proteins 
C, S, and Z 
Confidex, 4-factor PCC [110] CSL Behring GmbH Pasteurization 100–200 Antithrombin, heparin, proteins 
C and S 
Prothrombinex® VF, 3-factor 
PCC [102] 
CSL Behring (Australia) Pty Ltd., CSL 
Bioplasma 
Dry heat, nanofiltration 100 Antithrombin, heparin, low 
levels of factors V and VII 
Profilnine®, 3-factor PCC [103] Grifols Biologicals Inc. Solvent detergent, nanofiltration 100 Antithrombin, low levels of 
factor VII 
Uman Complex DI, 3-factor PCC Kedrion SpA Solvent detergent, dry heat 80 Antithrombin, heparin, proteins 
S, C, and Z 
Kaskadil, 4-factor PCC [107] LFB Biomedicaments Solvent detergent 160 Heparin, proteins S and C 
Kanokad, 4-factor PCC [104] LFB Biomedicaments  56–140 Proteins S and C 
Octaplex®/Ocplex®/Pronativ® 
4-factor PCC [105] 
Octapharma Limited Solvent detergent, nanofiltration 72–120 Heparin, proteins C, S, and Z; low 
activated factor VII 
Cofact, 4-factor PCC [106] Sanquin Plasma Products BV Solvent detergent, nanofiltration 56–140 Antithrombin, proteins C, S, and 
Z 
Kcentra®, 4-factor PCC [111] CSL Behring Heat, nanofiltration 125–165 Antithrombin, heparin, proteins 
S and C 
Three-factor PCC products contain factors II, IX, and X; 4-factor PCC products contain factors II, VII, IX, and X. 
NA, not available; PCC, prothrombin complex concentrate. 
a Not all products were/are available in all markets. 
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The approval of this product followed the successful outcomes of two 
pivotal phase 3 trials (designated TEN01 and TEN03; ClinicalTrials.gov 
identifiers NCT00930176 and NCT01086852, respectively) in a total of 
18 subjects with mild to severe hereditary factor X deficiency 
[31,59,62–64]. 
In order to provide a more comprehensive understanding of the 
safety of pdFX, an analysis was conducted across the three prospective 
clinical trials, together with postmarketing data (spontaneously re-
ported adverse reactions), with up to 4 years of follow-up [65]. Across 
the clinical trials, 18 subjects aged ≥12 years and 9 children aged <12 
years received pdFX over a total of 2495 days of exposure, with six 
treatment-emergent adverse reactions (all nonserious) observed in two 
subjects. In the analysis of postmarketing data through September 16, 
2017, an estimated 2925 pdFX infusions were administered over 105 
patient-years; there were three case reports of nine nonserious adverse 
reactions, with no inhibitor development and no thromboembolic 
events, and the authors concluded the good safety profile of pdFX in 
clinical trials. 
No cases of thrombosis or inhibitor development were reported with 
pdFX treatment in clinical studies, including with up to 4 years of 
treatment [62,63,66,67]. 
4.6. Prophylactic treatment 
Prophylactic therapy is recommended in patients with severe factor 
X deficiency, particularly those at risk for severe bleeding episodes such 
as CNS and GI bleeding, hematoma, and hemarthrosis [1]. This recom-
mendation is based on beneficial effects observed across several case 
series using various prophylactic strategies. Data from the Greifswald 
registry showed that bleeding episodes in seven patients with factor X 
deficiency were reduced using Factor IX HS at doses of 15–20 IU/kg 
factor X weekly, while control of joint bleeding required treatment 2–3 
times per week, and two patients received prophylaxis every other day 
[56]. Similarly, bleeding symptoms in 10 patients with severe factor X 
deficiency were significantly reduced in a study of prophylaxis using 20 
IU/kg Behring Factor X P concentrate weekly [55]. In addition, pro-
phylactic PCC therapy at FX doses of 50–70 IU/kg once or twice weekly 
achieved hemostasis in four neonates with severe factor X deficiency 
(with umbilical cord bleeding, intraperitoneal hemorrhage, and/or 
intracranial bleeding) [1,42] and three children with recurrent 
hemarthrosis and intracranial hemorrhage (described further in Sect. 
5.3) [8,16,68]. Additional individual cases of successful use of PCC 
prophylaxis have also been reported, including an adult patient with 
severe factor X deficiency who received a dose of 30 IU/kg twice weekly 
to prevent joint bleeding [1,69]. In other reports, PCC doses providing 
15–40 IU/mL factor IX 2–3 times weekly exhibited greater efficacy than 
doses delivering 20–70 IU/mL once weekly [4]. While the optimal 
dosing regimen for PCC remains to be confirmed, the higher risk of 
major spontaneous bleeding observed in the EN-RBD registry at factor X 
levels <10% suggest that factor X ≥ 10% is an appropriate target level 
for prophylaxis [12]. 
However, the most authoritative data on prophylactic therapy come 
from the results of a 6-month, open-label, multicenter, prospective 
phase 3 study of pdFX prophylaxis in 9 children aged <12 years with 
confirmed diagnosis of moderate to severe hereditary factor X deficiency 
(ClinicalTrials.gov identifier NCT01721681) [67]. Eight subjects with 
severe factor X deficiency (baseline FX:C < 1 IU/dL) and one with 
moderate factor X deficiency (baseline FX:C = 1 IU/dL) were enrolled to 
receive routine prophylaxis at a recommended dose of 40–50 IU/kg 
twice weekly to maintain trough FX:C levels >5 IU/dL (with peak levels 
≤120 IU/dL). Incremental recovery was significantly lower at each time 
point in younger subjects (0–5 years) than in older subjects (6–11 years; 
p < 0.05). Following the first dose, mean incremental recovery was 1.45 
in subjects aged 0–5 and 1.83 in subjects aged 6–11, both of which are 
lower than the mean incremental recover in subjects aged 12 or older 
(2.04) [59]. There were 10 bleeds during the study (6 minor, 3 major, 
and 1 of unrecorded severity) in 3 subjects, of which 4 bleeds in 2 
subjects were treated with a single infusion of pdFX (mean dose ±
standard deviation, 35.3 ± 7.2 IU/kg). The investigators rated the pro-
phylactic efficacy of pdFX (primary endpoint) as excellent (defined as no 
minor or major bleeds during the study period or a lower frequency of 
bleeds than expected given the subject’s medical/treatment history) for 
all subjects in the per-protocol population (those with ≥50 days of 
exposure and ≥26 weeks of treatment). The safety profile was consistent 
with previous studies conducted in subjects aged ≥12 years [65]. 
Further evidence of the efficacy of pdFX prophylaxis was also found 
in a retrospective analysis of 15 subjects with hereditary factor X defi-
ciency who received pdFX on a compassionate-use basis (TEN05), which 
is described in Sect. 4.4. This study included seven subjects given pdFX 
for routine prophylaxis (defined as regular doses of 25 IU/kg at least 
once/week) and one subject who alternately received prophylactic and 
on-demand treatment [66]. Four of the eight subjects given routine 
pdFX prophylaxis experienced bleeds (mean, 2.1 bleeds per patient total 
and 0.09 bleeds per patient per month). This bleed frequency was lower 
than that among subjects given on-demand therapy, whereas the mean 
dose of pdFX given to treat the bleeds was slightly higher (26.7 vs 20.5 
IU/kg, respectively) [66]. Like on-demand treatment, prophylactic 
therapy was not associated with any adverse drug reactions, safety 
concerns, infusion site reactions, tolerability issues, or inhibitor devel-
opment [66]. 
5. Special situations 
5.1. Women and girls with factor X deficiency 
In addition to exhibiting the general bleeding symptoms associated 
with factor X deficiency, women and girls with this disorder may also 
experience heavy menstrual bleeding and complications associated with 
pregnancy and childbirth [70]. Therapeutic options for control of heavy 
menstrual bleeding have included antifibrinolytics, a levonorgestrel 
intrauterine system, oral and hormonal contraceptives, and clotting 
factor replacement, as well as surgical procedures such as endometrial 
ablation and hysterectomy [70]. In a post hoc analysis of the efficacy, 
safety, and pharmacokinetics of pdFX in 16 subjects from study TEN01 
with moderate or severe factor X deficiency, pdFX treatment was 
effective at treating spontaneous bleeding as well as bleeding due to 
injury or menstruation in the 10 women and girls (aged 14–58 years); 
across 132 assessable bleeding episodes in women and girls (55.3% 
major bleeds, 43.9% minor, and 0.8% uncategorized), there was a 98% 
treatment success rate, defined as an investigator-rated response of 
“excellent” or “good” [71], with a total of 267 pdFX infusions (178 for 
on-demand treatment and 89 preventive infusions) administered. 
Women and girls received more infusions per month (2.48) than men 
and boys (1.62); treatment of bleeds required a mean of 1.58 infusions 
per month per woman/girl (vs 0.65 infusions per month for each man/ 
boy) and an average dose of 30.5 IU/kg pdFX [71]. 
Although factor X levels are known to rise during pregnancy, women 
with severe factor X deficiency and a history of adverse outcomes (e.g. 
spontaneous abortion, placental abruption, or premature birth) usually 
require replacement therapy to maintain hemostasis at delivery, 
together with appropriate monitoring to minimize the risk of thrombotic 
complications (particularly in those given PCCs) [1,3,4]. The use of 
PCCs or FFP as factor X replacement therapy during pregnancy has also 
been reported, but with highly variable regimens, as described else-
where [4,8,72]; in one series of 13 cases, the complication rate was 
relatively high, with two women experiencing postpartum hemorrhage, 
though there were no cases of thrombosis [8,73]. In addition to PCC use, 
one case of plasma exchange with FFP prior to cesarean delivery in a 
pregnant patient with severe factor X deficiency has been reported [72]. 
In another case report, the safe and effective use of pdFX treatment to 
maintain hemostasis during pregnancy and delivery was described in a 
patient with factor X deficiency (basal FX:C < 5 IU/dL) who had 
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participated in a phase 3 trial of on-demand/prophylactic pdFX use and 
was receiving 1500 IU pdFX (approximately 23 IU/kg) twice weekly 
under a compassionate-use program. Following four spontaneous 
abortions (three unconfirmed), the patient reported another pregnancy. 
The frequency of pdFX treatment was increased to three times weekly to 
prevent nose bleeds and protect the pregnancy, with twice-weekly 
administration resuming 3 weeks after healthy, uncomplicated de-
livery (spontaneous labor supported by an additional 1500 IU dose of 
pdFX) [74]. 
Published recommendations for this patient population include 
aggressive factor X replacement therapy in women with severe defi-
ciency and a history of adverse outcome in pregnancy, and assaying of 
factor X levels in pregnant heterozygous women prior to delivery to 
assess the bleeding risk, followed by assaying of factor X levels in cord 
blood at birth for the neonate, with retesting at 6 months of age [3]. 
Antenatal prophylaxis should be considered in pregnancy in women 
with severe factor X deficiency and a history of recurrent bleeding or 
adverse pregnancy outcomes. Expert consensus UK guidance recom-
mends the maintenance of factor X activity >30 IU/dL following de-
livery in women with low factor X levels and a history of bleeding, as 
well as in all women requiring cesarean section [74]. 
5.2. Surgery 
The evolution of treatment for patients with severe factor X defi-
ciency undergoing surgery followed the same pattern as that described 
in Sect. 4 above, with early cases managed using FFP, PCCs, and factor 
IX/X concentrate [32] prior to factor X concentrate becoming available. 
However, data associated with the use of PCCs and/or infusions of FFP 
are confined to individual case reports in which hemostasis during 
surgery was achieved with this treatment modality, maintaining post-
operative factor X levels at 10–40 IU/dL [32,75–78]. 
The efficacy and safety of pdFX for perioperative bleeding manage-
ment has been evaluated as part of two prospective, open-label phase 3 
studies involving five subjects aged 14–59 years undergoing seven sur-
gical procedures: two subjects participating in study TEN01 who each 
underwent two procedures and three subjects from study TEN03 who 
each underwent one procedure [63]. Factor X deficiency was severe (FX: 
C levels <1 IU/dL) in two subjects, moderate (FX:C ≥ 1 to <5 IU/dL) in 
one patient, and mild in two subjects (FX:C 6 and 8 IU/dL, respectively), 
all with a history of bleeding after surgery or spontaneous bleeding. All 
subjects were given pdFX infusion to raise plasma FX:C levels to 70–90 
IU/dL 1–4 hours before surgery. For all surgeries (four major and three 
minor), no blood transfusions were required, the investigator evaluation 
of hemostatic efficacy was “excellent” (defined in terms of parameters 
similar to those in subjects without a bleeding disorder), and no addi-
tional pdFX infusions were given during surgery [63]. In this study, FX:C 
levels were maintained above 50 IU/dL until the subject was no longer 
considered to be at risk of postoperative bleeding. (This lower limit of 
50 IU/dL is higher than that traditionally considered sufficient for he-
mostasis: FX:C levels of 0.1–0.2 IU/mL [10–20 IU/dL] are generally 
regarded as sufficient for subjects undergoing surgery, though this is 
based on very little evidence [3,32].) There were no adverse drug re-
actions, hypersensitivity reactions, thrombotic events, or evidence of 
inhibitor development [63]. 
In addition, the compassionate-use study described in Sect. 4.4 
(study TEN05) included three subjects receiving pdFX as presurgical 
hemostatic cover [66]. Two subjects each underwent a dental procedure 
and received a single presurgical pdFX infusion (27.1 and 28.5 IU/kg), 
and one patient underwent a port-a-cath insertion and required six in-
fusions to maintain hemostasis (72.8 IU/kg presurgically and five in-
fusions of 48.5 IU/kg on postsurgical days 1, 2, 3, 5, and 15) [66]. These 
subjects were included together with others receiving compassionate 
use in the analysis of efficacy (rated as “excellent” or “good” for all 
subjects) and safety, as reported in section 4.5 [66]. 
5.3. Intracranial bleeding 
Intracranial hemorrhage has been reported in 9%–26% of patients, 
most commonly in neonates, and seems to be associated with the 
occurrence of Gly380Arg mutation in particular [1,8,16,17,19]. Man-
agement following intracranial hemorrhage has primarily focused on 
PCC prophylaxis [8,16,68,79], though FFP has also been used with some 
success [78]. The findings of several cases reviewed by Brown et al. were 
variable, with no further bleeding seen in two reports in a total of five 
children with intracranial hemorrhage treated with PCC doses of 40–70 
U/kg factor IX once or twice weekly [42,79], but inadequate efficacy 
observed in two other children treated with PCC weekly or twice weekly 
[43]. In addition, in a report of three cases of severe congenital factor X 
deficiency (FX:C < 1 IU/dL) in neonates with spontaneous life- 
threatening intracranial hemorrhage, FFP infusion was of limited 
benefit, and patients were treated with activated PCC prophylaxis at 50 
IU/kg doses administered twice weekly for 10, 4, and 2 years, respec-
tively, with no new bleeding episodes observed [68]. 
With the development of single-factor concentrates, a case has also 
recently been reported of a 20-year-old male with severe factor X defi-
ciency who experienced a subdural hematoma that was effectively 
treated with 15 IU/kg pdFX. After recovery, the patient received weekly 
routine prophylaxis with 25 IU/kg pdFX [80]. 
Because of the high risk of intracranial hemorrhage in neonates with 
severe factor X deficiency, cranial ultrasound scanning has been rec-
ommended, together with prophylactic replacement therapy prophy-
laxis, though the authors warn that hemorrhage may still occur even 
with these measures [3]. 
6. Other considerations: acquired factor X deficiency 
Acquired factor X deficiency can be caused by primary amyloidosis 
(occurring in up to 14% of patients with amyloidosis), severe liver dis-
ease, or vitamin K antagonist therapy (in association with other coag-
ulation factor deficiencies) [2,8]. In addition, acquired inhibitors to 
factor X have been identified in patients with burns, respiratory in-
fections, or exposure to topical thrombin [8]. The clinical characteris-
tics, common comorbidities, and typical symptoms of patients with 
acquired factor X deficiency have been summarized in previous reviews 
[2,81], supplemented by more recent analyses (e.g. by Patel et al. [82]). 
In brief, bleeding manifestations resemble those in patients with he-
reditary factor X deficiency and show marked heterogeneity; however, 
bleeding tendency is not always correlated with FX:C levels in these 
patients, unlike those with hereditary factor X deficiency [2]. 
The presence of a specific inhibitor has been observed in some pa-
tients with acquired factor X deficiency [1,2], suggested by anomalous 
findings, such as factor X assays that are inconsistent with the extent of 
hemorrhagic symptoms. Testing for inhibitory activity typically involves 
mixing patient and normal plasmas and measuring factor X activity 
following dilution; additional tests may also include ELISA testing for 
immunoglobulin M and G antiphospholipid antibodies and platelet 
neutralization testing [83,84]. 
Unlike the hereditary form of the disease, acquired factor X defi-
ciency appears to be short-lived, with some patients even demonstrating 
spontaneous normalization of coagulation tests; all of the cases 
described by Lee et al. [2] demonstrated a complete recovery, and none 
required long-term therapy for factor X deficiency. However, at least one 
case has subsequently been reported of fatal bleeding due to acquired 
factor X and IX deficiencies [85]. 
There is no standardized treatment for acquired factor X deficiency 
[2]. Limited, variable success has been achieved with vitamin K plus 
FFP, PCCs (with dosing frequency and disease severity each playing a 
role in treatment efficacy), dual-factor concentrate, or recombinant 
activated factor VIIa with oral corticosteroids [2,86–94]. Treatments 
targeting the underlying primary conditions have been successful for 
some patients, including patients with inflammatory bowel disease, 
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malignancy, or infections, along with removal of precipitant medica-
tions [2]. In addition, a few cases have been reported of improvement on 
treatment with various other treatment approaches: FFP and vitamin K; 
high-dose glucocorticoids; alpha amino-caproic acid or recombinant 
activated factor VII in conjunction with prednisolone; factor IX complex 
in combination with activated clotting factor, PCCs, and prednisolone; 
intravenous immunoglobulin; and therapy targeted at removing specific 
inhibitors and suppressing the immune system in patients with sus-
pected inhibitors [2]. 
Recently, two cases have been reported of the successful treatment of 
acquired factor X deficiency in patients with systemic light-chain 
amyloidosis with pdFX; the findings indicated that higher and/or 
more frequent dosing may be required for hemostasis, with frequent 
monitoring of factor X levels to achieve target thresholds similar to those 
in patients with hereditary factor X deficiency (10–16 IU/dL for minor 
bleeding and 50 IU/dL for major bleeding, trauma, or surgery [95]. 
However, pdFX is not approved for the treatment of acquired factor X 
deficiency. 
7. Conclusions and recommendations 
Factor X deficiency is among the most serious of the rare bleeding 
disorders, particularly in neonates and small children with severe factor 
X deficiency, who are at risk of life-threatening bleeds within the first 
weeks and months of life. It is a highly heterogeneous disorder, both as a 
hereditary disease and as an acquired deficiency. The treatment of factor 
X deficiency has evolved over recent years, with the development of 
pdFX representing the most recent advance. While the patient numbers 
in clinical studies are limited due to the rarity of the disease, evidence to 
date indicates that single-factor therapy with pdFX provides advantages 
over previously used multiple-factor therapies such as FFP and PCCs, 
which may fail to achieve adequate hemostasis due to dose limitations 
associated with the risks of volume overload with FFP (especially in 
neonates and small children with severe deficiency and life-threatening 
bleeds), anaphylaxis, and thrombosis. 
Current prescribing information for available therapies provides 
limited guidance on dosing in the treatment of factor X deficiency, 
whether hereditary or acquired. (See Table 2 for current guidance on 
dosing derived from various sources.) The most specific information is 
given in the prescribing information for pdFX for routine prophylaxis to 
reduce the frequency of bleeding episodes, on-demand treatment to 
control bleeding episodes, and peri- and postoperative management of 
bleeding, which includes recommendations of target plasma factor X 
levels of 70–90 IU/dL and 50 IU/dL for pre- and postoperative periods, 
respectively [59]. A minimum threshold of 10–20 IU/dL has been sug-
gested to provide adequate hemostasis for bleeding prophylaxis and in 
the treatment of minor bleeding [3,32,95]. 
For pregnant women (or women wishing to conceive) who have se-
vere factor X deficiency and a history of recurrent bleeding or adverse 
pregnancy outcomes, antenatal prophylaxis should be considered. The 
authors suggest prophylactic therapy with pdFX to maintain trough 
levels of factor X above 20 IU/dL until the end of pregnancy; this 
approach has been successful in four pregnancies to date in women with 
severe factor X deficiency ([74] and unpublished observations). In 
addition, expert consensus UK guidance recommends the maintenance 
of factor X activity above 0.3 IU/mL (or 30 IU/dL) following delivery in 
women with low factor X levels and a history of bleeding, as well as in all 
women requiring cesarean section. 
8. Future considerations 
Clearly, further research is necessary to define the optimal factor X 
threshold levels in other scenarios with all available treatment options. 
With the advent of new therapies and advances in the formulation of 
PCCs and other factor replacement therapies (including the use of 
additional constituents), there is now an urgent need to achieve 
Table 2 
Dosages of replacement therapies used in the treatment of severe factor X 
deficiency.  
Treatment Indication Dosage 
Single-factor pdFX 




of bleeding episodes 
Children <12 years: 30 IU/kg 
Adults/adolescents ≥12 years: 
25 IU/kg 
For all: repeat at intervals of 





Dose to target FX levels of 
70–90 IU/dLa [59,60] 
Postoperative 
bleeding 
Dose to target FX levels of 50 
IU/dLa [59,60] 
Prophylaxis and 
control of minor 
bleeds 
Children <12 years: 40 IU/kg 
twice weekly 
Adults/adolescents ≥12 years: 
25 IU/kg twice weekly 
For all: monitor trough blood 
levels of FX targeting ≥5 IU/dL 
and adjust dosage to clinical 
response and trough levels. Do 
not exceed a peak level of 120 
IU/dL [59,60] 
Dual-factor IX/X therapy 
(Behring X P) [52] 
Control of bleeding 
episodes 
Dose to target FX levels of 




Dose to target FX levels of 
20–40 IU/kg once or twice 
weeklyb 
Multifactor replacement 
therapy (FIX HS, ZLB 
Behring) [56] 
Prophylaxis in 
patients with severe 
bleeds 
15–20 IU FIX/kg once weekly 
Control of joint 
bleeding 
15–20 IU FIX/kg 2 or 3 times 
weekly 
Multifactor replacement 
therapy (AlphaNine SD, 
Grifols Biologicals) 
[54] 
Surgery 50–100 IU FIX/kg twice daily 
for up to 10 days 
Major hemorrhage 30–50 IU FIX/kg twice daily 
for up to 10 days 
Moderate 
hemorrhage 
25–50 IU FIX/kg twice daily 
for 2–7 days 
Minor hemorrhage 20–30 IU FIX/kg twice daily 
for 1–2 days 




Dose calculated based on 
empirical findings of 1.5% 
increase in FX per 1 IU FX/kg 
dosec,d 




30 IU/kg for up to 2 doses in 
24 h or daily for 3 days 
Regular prophylaxis 30 IU/kg twice weekly 
FFP [3] Replacement 
therapy 
Dose to target trough FX levels 
above 10–20 IU/d (20 mL/kg 
followed by 3–6 mL/kg twice 
daily) 
Surgery 35 IU/dL preoperatively and 
dose to target 5–20 IU/dL 
postoperatively 
FFP, fresh frozen plasma; FIX, factor IX; FX, factor X; IU, international units; 
PCC, prothrombin complex concentrate; pdFX, plasma-derived factor X 
concentrate. 
a The dose to achieve a desired in vivo peak increase in factor X level may be 
calculated using the following formula: for individuals ≥12 years: dose (IU) =
body weight (kg) × desired factor X rise (IU/dL or % of normal) × 0.5; for young 
children (<12 years of age): dose (IU) = body weight (kg) × desired factor X rise 
(IU/dL) × 0.6. 
b Required dose (IU factor IX) = body weight (kg) × desired rise in factor X 
(IU/dL) × 1.21. 
c Recommendations from the UK Haemophilia Centre Doctors’ Organization. 
d Please refer to Table 1 for FX content of individual PCC products. 
F. Peyvandi et al.                                                                                                                                                                                                                               
Blood Reviews xxx (xxxx) xxx
8
consensus in treatment guidelines to ensure optimal management of 
patients with severe and mild forms of the disease alike. 
Practice points  
• Factor X deficiency is a highly heterogeneous rare bleeding disorder, 
with serious and life-threatening consequences, particularly in neo-
nates and small children.  
• The treatment of factor X deficiency has evolved substantially, from 
plasma replacement therapy (fresh frozen plasma) to prothrombin 
complex concentrates (PCCs) to, most recently, the development and 
licensing approval of a high-purity, plasma-derived, specific single- 
factor concentrate (pdFX). While patient numbers are small, clin-
ical studies have demonstrated the ability of pdFX therapy to 
improve hemostasis while limiting the safety concerns associated 
with earlier treatments such as volume overload (particularly in 
neonates and young children), anaphylaxis, and thrombosis.  
• Given the rarity of the disease, there is limited guidance on optimal 
therapy and dosing across the spectrum of patient needs, i.e. for 
routine prophylaxis to reduce the frequency of bleeding episodes, on- 
demand treatment in the control of bleeding episodes, peri- and 
postoperative management of bleeding, special situations such as 
pregnancy, acquired factor X deficiency, and management of serious 
concerns such as intracranial hemorrhage.  
• With the advent of new therapies, advances in the formulations or 
inclusion of additional constituents in PCCs and other factor 
replacement therapies, and the potential for new non-replacement 
therapeutic approaches, there is now an urgent need to achieve 
consensus in treatment guidelines to ensure optimal management of 
patients with severe, moderate, or mild forms of the disease in all 
scenarios. 
Research agenda  
• Thresholds of FX activity that can define severity of disease.  
• Optimal treatment approaches across the spectrum of disease 
severity.  
• Minimal amount of FX needed to prevent early bleeding.  
• Optimization of prophylaxis.  
• Optimization of treatment for women with FX deficiency in terms of 
preventing menorrhagia and of having a safe pregnancy. 
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